CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M

Positive
AI Analysis

Summary

GSK acquires a trispecific T cell engager program targeting multiple myeloma from Chimagen Biosciences in a deal worth up to $750 million, expanding their oncology portfolio following an earlier T cell engager collaboration.

Importance:7/10
Sentiment:
0.60
acquisitionT cell engagermultiple myelomatrispecific antibody
Related Companies

Read the original article

Published by BioSpace on September 15, 2026 1:33 PM

Read Original